(3S,5S)-Atorvastatin (sodium salt) |
| رقم الكتالوجGC13751 |
negetive control of Atorvastatin, HMG-CoA reductase inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1428118-38-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Atorvastatin exists in four optical forms. The (3R, 5R)-atorvastatin enantiomer displays the greatest activity against HMG-CoA reductase. (3S,5S)-Atorvastatin is an enantiomer of atorvastatin with little or no inhibitory activity against HMG-CoA reductase [1]. Atorvastatin is a synthetic HMG-CoA reductase inhibitor implicated in lowering plasma cholesterol levels by inhibiting endogenous cholesterol synthesis. Atorvastatin also reduces triglyceride levels through an as yet unproven mechanism [2]. In various trials in patients with hypercholesterolaemia, atorvastatin produced greater reductions in total cholesterol, apolipoprotein B, LDL-cholesterol and triglyceride levels. In patients with primary hypercholesterolaemia, atorvastatin in combination with colestipol produced significant reductions in LDL-cholesterol levels and smaller reductions in triglyceride levels than atorvastatin monotherapy [2].
References:
[1] Kocarek T A, Dahn M S, Cai H, et al. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes[J]. Drug Metabolism and Disposition, 2002, 30(12): 1400-1405.
[2] Lea A P, McTavish D. Atorvastatin[J]. Drugs, 1997, 53(5): 828-847.
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *